Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.41)
# 850
Out of 4,826 analysts
170
Total ratings
44.24%
Success rate
3.21%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRRO Korro Bio | Initiates: Overweight | $74 | $17.67 | +318.79% | 2 | Apr 29, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $7.71 | +29.70% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $18.66 | +50.05% | 1 | Apr 29, 2025 | |
| ATXS Astria Therapeutics | Initiates: Overweight | $47 | $5.13 | +817.07% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.65 | +507.90% | 14 | Apr 29, 2025 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | $20 | $11.03 | +81.32% | 1 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $29.49 | +252.66% | 19 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $1.56 | +1,310.26% | 2 | Dec 11, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $21.55 | +159.86% | 3 | Nov 8, 2024 | |
| ETNB 89bio | Maintains: Strong Buy | $53 → $49 | $8.61 | +469.11% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $1.80 | +679.94% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $102.81 | -9.54% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $25.48 | +166.88% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $19.98 | +430.53% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $3.74 | +301.61% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $11.84 | +373.17% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $78 → $64 | $44.12 | +45.06% | 18 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.38 | +4,505.26% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $8.45 | +574.96% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $1.44 | +1,433.10% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $1.54 | +1,003.90% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $7.84 | +346.71% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $33.63 | +12.99% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $32.28 | +119.95% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $1.25 | +300.00% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $20.77 | +82.96% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $11.91 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.33 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $121.80 | - | 2 | Apr 23, 2020 | |
Korro Bio
Apr 29, 2025
Initiates: Overweight
Price Target: $74
Current: $17.67
Upside: +318.79%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $7.71
Upside: +29.70%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $18.66
Upside: +50.05%
Astria Therapeutics
Apr 29, 2025
Initiates: Overweight
Price Target: $47
Current: $5.13
Upside: +817.07%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.65
Upside: +507.90%
BioCryst Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $20
Current: $11.03
Upside: +81.32%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $29.49
Upside: +252.66%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $1.56
Upside: +1,310.26%
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $21.55
Upside: +159.86%
89bio
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $8.61
Upside: +469.11%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.80
Upside: +679.94%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $102.81
Upside: -9.54%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $25.48
Upside: +166.88%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $19.98
Upside: +430.53%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $3.74
Upside: +301.61%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $11.84
Upside: +373.17%
Dec 19, 2023
Maintains: Strong Buy
Price Target: $78 → $64
Current: $44.12
Upside: +45.06%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.38
Upside: +4,505.26%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $8.45
Upside: +574.96%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $1.44
Upside: +1,433.10%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $1.54
Upside: +1,003.90%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $7.84
Upside: +346.71%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $33.63
Upside: +12.99%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $32.28
Upside: +119.95%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $1.25
Upside: +300.00%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $20.77
Upside: +82.96%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $11.91
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.33
Upside: -
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $121.80
Upside: -